Roche raised the curtain on its novel approach to DNA sequencing earlier this year, and now it's working with the Broad ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Innate Pharma has claimed long-term data from a phase 2 study show that its anti-KIR3DL2 antibody has a “sustained effect” ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

Johnson & Johnson has put forward a clinical study exploring the use of its Shockwave Medical division’s vessel-clearing ...